Drawing for ASEDASCIENCES

USPTO serial 79130387

ASEDASCIENCES

Reviewed by CopyMark Law Group

Reg. 4541102Status 706Registered
Filing date
Status date
Registration date
Jun 3, 2014
Examiner
PARKS, KIMBERLY L
Law office
Historical data usage

What this means

This trademark is registered with the USPTO. Monitoring new filings can help you catch lookalike marks early.

Need help with ASEDASCIENCES?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Jeffrey A. Smith

Jeffrey A. Smith MILLEN, WHITE, ZELANO, AND BRANIGAN, PC2200 CLARENDON BOULEVARDSUITE 1400ARLINGTON, VA 22201-3360

Goods and services

ClassDescriptionStatusFirst use
005[ In vitro diagnostic preparations for medical use; diagnostic test reagents for medical use; chemical reagents for medical or veterinary use; diagnostic reagents and contrast media agents for medical use; Medical diagnostic reagents; Reagents for medical use ]SECTION 71 - CANCELLED—
009[ Measuring apparatus and instruments, namely, free flow electrophoresis equipment for protein separation and isolation, and flow cytometry analyzers for cellular analysis; scientific, optical, measuring, signaling and checking apparatus and instruments, namely, free flow electrophoresis equipment for protein separation and isolation, and flow cytometers for single cell and population based cellular analysis; measuring and testing machines and instruments, namely, protein separation and isolation instruments, flow cytometers, and laboratory liquid handlers and automation for testing and implementing cellular based screening methods; laboratory apparatus and instruments for use in growing, maintaining, evaluating and quality control of cell cultures, automated liquid dispensing, protein separation and isolation, single cell and population based cellular analysis, and the assessment of compound or drug effects on cellular physiology and biology, not for medical purposes; chemistry apparatus and instruments for maintaining, evaluating and quality control of cell cultures, automated liquid dispensing of compound preparations and chemical reagents, protein separation and isolation, single cell and population based cellular analysis, and the assessment of compound or drug effects on cellular physiology and biology, not for medical purposes ]SECTION 71 - CANCELLED—
042Scientific research and development; scientific and technological services, namely, novel multi-parametric phenotypic screening in the nature of analytical testing services and protein isolation for the characterization and simultaneous identification of multiple biological and physiological effects caused by drug candidates on live human cell models in the field of pharmaceutical research, drug discovery and characterization of compound effect, and scientific research and development relating thereto; Scientific and technological services for scientific analysis, testing and research in the fields of pharmaceutical research [, drug discovery and characterization of compound effect, and protein separation, isolation and characterization ]; scientific research services; scientific testing and analysis in the fields of pharmaceutical research, drug discovery and characterization of compound effect [, and protein separation, isolation and characterization ]; computer-assisted scientific research, testing and analysis services in the fields of pharmaceutical research, drug discovery and characterization of compound effect by using mathematical and statistical algorithms to compare and predict the effect of a target compound to that of an approved drug or known toxin, where a biological fingerprint is created and analyzed by measuring the broad physiological and biological effect of said compounds on live human cells; laboratory research and analysis services in the fields of pharmaceutical research, drug discovery and characterization of chemical compounds, and protein separation, isolation and characterization; [ pharmaceutical research and development; ] Scientific research and scientific and technological services, namely, analytical testing and phenotypic screening services in the fields of pharmaceutical research, drug discovery and characterization of chemical compounds [, and protein separation, isolation and characterization ]; scientific laboratory services in the fields of pharmaceutical research, drug discovery and characterization of chemical compounds [, and protein separation, isolation and characterization ]; scientific and technological services, namely, analytical testing and phenotypic screening services in the fields of pharmaceutical research, drug discovery and characterization of chemical compounds, and protein separation, isolation and characterization; [ provision of information about medical and scientific research in the field of pharmaceuticals; preparation of reports on scientific research; ] provision of scientific information on technological research in the fields of pharmaceutical research, drug discovery and characterization of chemical compounds; [ provision of scientific information about industrial analysis and research services in the fields of pharmaceutical research, drug discovery and characterization of chemical compounds; provision of information and data relating to medical research and development and veterinary medical research; consultancy services in the field of pharmaceutical research; consultancy relating to research and development in the field of therapeutics; engineering and ] scientific consultancy services in the fields of pharmaceutical research, drug discovery and characterization of chemical compounds [, and protein separation, isolation and characterization; provision of technical advice in the field of scientific and industrial research; consultancy in the field of scientific and industrial research ]ACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Feb 14, 2025INPRPARTIAL INVALIDATION OF REG EXT PROTECTION CREATED—
Jun 13, 2024NA71NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED—
Jun 13, 202471AGREGISTERED-SEC.71 ACCEPTED—
Jun 3, 2024ES71TEAS SECTION 71 RECEIVED—
Jun 7, 2023LIMNLIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED—
Jun 3, 2023REM4COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED—
Mar 31, 2023RNWLINTERNATIONAL REGISTRATION RENEWED—
Mar 27, 2023LIMGLIMITATION OF GOODS RECEIVED FROM IB—
May 29, 2022INNPPARTIAL INVALIDATION PROCESSED BY THE IB—
Apr 3, 2022INPSPARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB—
Apr 3, 2022INPCINVALIDATION PROCESSED—
Nov 15, 2021INPRPARTIAL INVALIDATION OF REG EXT PROTECTION CREATED—
Mar 15, 2021NA75NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED—
Mar 15, 2021C75PREGISTERED - PARTIAL SEC. 71 ACCEPTED & SEC. 15 ACK.—
Feb 1, 2021APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Dec 3, 2020ES75TEAS SECTION 71 & 15 RECEIVED—
Jun 3, 2019REM3COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED—
Nov 28, 2014FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Oct 27, 2014FICSFINAL DISPOSITION NOTICE SENT TO IB—
Oct 27, 2014FIMPFINAL DISPOSITION PROCESSED—
Sep 3, 2014FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Jul 31, 2014ADCHCHANGE OF NAME/ADDRESS REC'D FROM IB—
Jun 3, 2014R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Mar 18, 2014NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Mar 18, 2014PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Mar 14, 2014GPNXNOTIFICATION PROCESSED BY IB—
Feb 26, 2014OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Feb 26, 2014OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB—
Feb 26, 2014NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Feb 8, 2014PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Feb 8, 2014ALIEASSIGNED TO LIE—
Jan 21, 2014CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Dec 18, 2013XAECEXAMINER'S AMENDMENT ENTERED—
Dec 18, 2013GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Dec 18, 2013GNEAEXAMINERS AMENDMENT E-MAILED—
Dec 18, 2013CNEAEXAMINERS AMENDMENT -WRITTEN—
Oct 2, 2013ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Oct 2, 2013REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Jul 22, 2013RFNTREFUSAL PROCESSED BY IB—
Jul 3, 2013RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Jul 3, 2013RFRRREFUSAL PROCESSED BY MPU—
Jul 3, 2013RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Jul 2, 2013CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 28, 2013DOCKASSIGNED TO EXAMINER—
Jun 11, 2013MAFRAPPLICATION FILING RECEIPT MAILED—
Jun 7, 2013NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jun 6, 2013REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance